Shots: The companies initiate P-III SANOVO study to evaluates the efficacy & safety of Orpathys in combination with AstraZeneca’s Tagrisso (irreversible EGFR TKI) vs Tagrisso alone in patients with NSCLC […]readmore
Tags : osimertinib
Shots: The approval is based on P-III ADAURA trial assessing Tagrisso (80mg, qd, PO) vs PBO in 682 patients with stage IB, II, IIIA EGFRm NSCLC following complete tumor resection […]readmore
Shots: AstraZeneca’s Tagrisso has received sNDA’s acceptance and has been granted PR in the US for the adjuvant treatment of patients with early-stage (IB, II, and IIIA) EGFRm NSCLC after […]readmore
Shots: The P-III ADAURA study involves assessing of Tagrisso (80mg, qd, PO) vs PBO for the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC following complete […]readmore
Shots: The BT designation is based on P-III ADAURA trial which involves assessing Tagrisso (80 mg) vs PBO in 682 patients with Stage IB, II, IIIA EGFRm NSCLC following complete […]readmore
Shots: The P-III ADAURA study involves assessing of Tagrisso (80 mg, qd) vs PBO in the adjuvant treatment of 682 patients with stage IB, II, and IIIA EGFRm NSCLC with […]readmore
Shots: The NMPA’s approval follows its PR pathway and is based on P-III FLAURA study assessing Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib [150mg, qd]/gefitinib [250mg, qd]) in 556 previously untreated […]readmore
Shots: The P-III FLAURA study involves assessing of Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib, 50mg, qd /gefitinib, 250mg, qd) in 556 patients with LA/metastatic EGFRm NSCLC across 29 countries In […]readmore